22nd Century Group (Nasdaq: XXII) to Host Investor Meetings at Roth Capital Conference March 14-15

Rhea-AI Summary

Roth Capital Partners has initiated research coverage on 22nd Century Group (Nasdaq: XXII), a leader in agricultural biotechnology focused on tobacco harm reduction.

CEO James A. Mish and CFO Richard Fitzgerald will host meetings on March 14-15, 2022, at the Roth Capital Annual Conference in Laguna Niguel, California.

The company is known for its reduced nicotine tobacco products and received the first FDA MRTP authorization for a combustible cigarette in December 2021, aiming to improve health through modern plant science.

Roth Capital Partners has initiated research coverage on 22nd Century Group.

BUFFALO, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced that James A. Mish, CEO, and Richard Fitzgerald, CFO, will host investor meetings March 14-15, 2022 as part of the Roth Capital Partners Annual Conference, taking place at The Ritz Carlton, Laguna Niguel in Dana Point, California.

Roth Agricultural Technology Analyst Brian Wright today initiated research coverage on 22nd Century Group.

Roth Capital events are intended for prospective and existing Roth Capital clients. To request a meeting, please contact your Roth Capital representative, or by contacting 22nd Century Group’s investor relations team via investorrelations@xxiicentury.com.

About 22nd Century Group, Inc.
22nd Century Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science. With dozens of patents allowing it to control nicotine biosynthesis in the tobacco plant, the Company has developed proprietary reduced nicotine content (RNC) tobacco plants and cigarettes, which have become the cornerstone of the FDA’s Comprehensive Plan to address the widespread death and disease caused by smoking. The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021. In tobacco, hemp/cannabis, and hop plants, 22nd Century uses modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding to deliver solutions for the life science and consumer products industries by creating new, proprietary plants with optimized alkaloid and flavonoid profiles as well as improved yields and valuable agronomic traits.

Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn.

Learn more about VLN^® at tryvln.com.

Cautionary Note Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2021. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law.

Investor Relations & Media Contact:
Mei Kuo
22nd Century Group, Inc.
Director, Communications & Investor Relations
T: 716-300-1221
mkuo@xxiicentury.com

Darrow Associates Investor Relations
Matt Kreps
T: 214-597-8200
mkreps@darrowir.com

FAQ

What is the significance of Roth Capital initiating coverage on XXII?

Roth Capital's initiation of coverage on 22nd Century Group (XXII) signals increased interest and potential growth in the agricultural biotechnology sector focused on tobacco harm reduction.

When will the CEO and CFO of XXII host investor meetings?

James A. Mish and Richard Fitzgerald will host investor meetings on March 14-15, 2022, during the Roth Capital Annual Conference.

What is 22nd Century Group's focus in biotechnology?

22nd Century Group focuses on tobacco harm reduction and reducing nicotine content in tobacco products, leveraging modern plant science.

What unique FDA authorization did XXII receive?

22nd Century Group received the first and only FDA MRTP authorization for a combustible cigarette in December 2021, demonstrating their commitment to reducing nicotine consumption.